Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers March 21, 2018
Pharmacy Choice - News - Over-the-Counter Drugs - March 21, 2018

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 106     Next >>     Go To Page:

3/14/18 - Federal Register Table of Contents
Table of Contents Office of the Federal Register Agency for Healthcare Research and Quality NOTICES Agency Information Collection Activities; Proposals, Submissions, and Approvals, 11203-11206 Agricultural Marketing Service RULES Honey Packers and Importers Research, Promotion, Consumer Education and Industry Information Order: Change in Producer..
3/14/18 - Medical Devices; Exemption From Premarket Notification; Class II Devices; Over-the-Counter Denture Repair Kit
FDA is publishing this order in accordance with the section of the Federal Food, Drug, and Cosmetic Act permitting the exemption of a device from the requirement to submit a 510. FOR FURTHER INFORMATION CONTACT: Rebecca Nipper, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 1540, Si
3/14/18 - Streamlining federal OTC regulations to improve public health N.C. Rep. Chris Malone: Streamlining federal OTC regulations to improve public health
You come down with a minor cold, and to seek relief from your symptoms, you stop by your local pharmacy. Within minutes you're out of the store, medicine in hand and on your way to feeling better- all without the need to call your doctor or get a prescription. Most OTC medicines are regulated by the U.S. Food and Drug Administration under what's ca
3/13/18 - INVOKANA (canagliflozin) Significantly Reduces the Risk of Heart Failure- Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease
Johnson and Johnson issued the following news release:. The Janssen Pharmaceutical Companies of Johnson& Johnson today announced results of a new analysis showing that INVOKANA (R) significantly reduced the risk of cardiovascular death or hospitalization for heart failure in patients with type 2 diabetes at high CV risk. "This new analysis from th
3/12/18 - Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs
Deep clinical pipeline of novel small molecule tyrosine kinase inhibitors: Eight clinical drug candidates now in active or completing clinical trials in 36 target patient populations around the world; over 3,500 subjects dosed in trials to date, over 700 in 2017; Stream of second-generation immunotherapy compounds advancing through pre-clinical...
3/12/18 - Findings Released From Largest Real-World Data Analysis of Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants
Pfizer, a pharmaceutical company, issued the following news release:. Bristol-Myers Squibb Company and Pfizer Inc. will present findings today from a real-world data analysis titled, Comparison of Effectiveness, Safety, and the Net Clinical Outcome between Different Direct Oral Anticoagulants in 162,707 Non-Valvular Atrial Fibrillation Patients...
3/12/18 - Global Active Pharmaceutical Ingredients Market Sales Is Growing at 6.3% CAGR Till 2022: Global active pharmaceutical ingredient market to reach USD 213.84 billion by 2021 and is growing at a CAGR of 6.3% during 2016-2021
Sarasota, FL 03/12/2018 Active pharmaceutical ingredient is used in the manufacturing of a pharmaceutical drug as a biologically active compound. API is an organic compound which has unique chemical structure and stereochemistry. Any medication is made up of two portions.
3/12/18 - Innovus Pharma Launches its New Brand, Logo and its Latest E-Commerce-Enhanced Content Website
By a News Reporter-Staff News Editor at Pharma Business Week First paragraph, second sentence should read: The new website can be found at The corrected release reads: INNOVUS PHARMA LAUNCHES ITS NEW BRAND, LOGO AND ITS LATEST E-COMMERCE-ENHANCED CONTENT WEBSITE New Website Features its Robust Beyond Human Sales& Marketing P
3/12/18 - Orexigen Therapeutics, Inc. Plans For Near-term Sale Using Structured Process Through Chapter 11 Of U.S. Bankruptcy Code
Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, announced today that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. Orexigen also intends to file a motion seeking authorization to pursue an auction and sale
3/12/18 - Perrigo Announces Final FDA Approval and Planned Launch for the Store Brand OTC Equivalent of Mucinex DM Maximum Strength Extended Release Tablets
DUBLIN- Perrigo Company plc today announced that it has received final approval from the U.S. Food& Drug administration for the store brand OTC equivalent of Mucinex DM Maximum Strength. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products.
3/11/18 - Findings Released from Largest Real-World Data Analysis of Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants
Eliquis use was associated with lower rates of stroke or systemic embolism and major bleeding than matched patients receiving rivaroxaban or dabigatran This oral presentation is one of nine Bristol-Myers Squibb-Pfizer Alliance abstracts being presented at the American College of Cardiology's 67th Annual Scientific Session& Expo.
3/11/18 - Great expectations for Vietnam's pharma firms [Vietnam Investment Review (VIR)]
Traphaco, the second-largest publicly-traded drug maker in Vietnam, aims to make a net consolidated profit of VND300 billion, and consolidated revenues of VND2.4 trillion this year, up 15.28 per cent and 28.47 per cent on-year, respectively. TRA, which has Vietnam Azalea Fund Ltd. as a major foreign shareholder with a 24.99 per cent stake, also aim
3/10/18 - Praluent (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate
TARRYTOWN, N.Y. and PARIS, March 10, 2018/ PRNewswire/ Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the ODYSSEY OUTCOMES trial met its primary endpoint, showing Praluent Injection significantly reduced the risk of major adverse cardiovascular events in patients who had suffered a recent acute coronary syndrome event, such as
3/10/18 - Regeneron and Sanofi Announce Plans to Make Praluent (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need
TARRYTOWN, N.Y. and PARIS, March 10, 2018/ PRNewswire/ To help ensure more affordable and timely access to patients most in need, Regeneron Pharmaceuticals and Sanofi will offer payers that agree to reduce burdensome access barriers for high-risk patients a further reduced net price for Praluent Injection, in alignment with a new value assessm
3/10/18 - Wize Pharma Receives IRB Approval of Phase IV Study Protocol for LO2A in Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjogren's Syndrome
By a News Reporter-Staff News Editor at Investment Weekly News Wize Pharma, Inc., a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, announced it has received Institutional Review Board approval for the protocol of its planned Phase IV study. The study will take place in Israel and will evaluate
3/9/18 - Innovus Pharma to Present at the Sachs BioCapital USA Forum at the New York Academy of Sciences
Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men s and women's health and respiratory diseases, today announced that Dr. Bassam Damaj, President and Chief Executive Officer and Rauly Gutierrez, Vice..
3/9/18 - New Anti-Diarrhea Drug Trend a New Threat
Dear Editor, A new trend has caught on across America. This has resulted in the Food and Drug Administration or FDA to release warnings over the last several weeks. One Doctor at Bay care Clinic in Wisconsin detailed the dangerous effects of the drug in an interview with ABC 2 WBAY.
3/9/18 - Nutra Pharma Announces Corporate Updates [Sudan Tribune]
-via OTC PR WIRE Nutra Pharma Corporation, a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV and that also markets the over-the-counter pain drugs; Nyloxin and Pet Pain-Away, announced today that they are in the process of restructuring their Board of Directors as well as their corporate debt to pave the way
3/9/18 - Over The Counter (OTC) Drugs Market - Latin America Industry Analysis, Size, Share, Growth, Trends and Forecast to 2023
PUNE, INDIA, March 9, 2018/ Presents Latin America Over The Counter Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023 New Document to its Studies Database. Over-the-counter drugs Market, also known as the non-prescription
3/9/18 - Two more OTC makers slammed with US FDA warnings [Arab Times (Kuwait)]
Both letters, sent by the US Food and Drug Administration on February 23, highlight violations of current good manufacturing practice regulations for finished pharmaceuticals observed during inspections of their respective plants. Nan San Pharmaceutical Factory Limited had its facility in Kowloon, Hong Kong inspected in September 2017 and was scold
3/9/18 - Yet among large segments of the general public, addiction li
Much of America, however, takes an opposing view, although happily Congress just included $6 billion in its recently passed budget for dealing with what is generally viewed as America's most pressing public health problem after cigarette smoking and alcohol, "The Opioids Crisis." Fortunately, the federal government is finally following the lead of.
3/8/18 - Nutra Pharma Announces Corporate Updates
via OTC PR WIRE Nutra Pharma Corporation, a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV and that also markets the over-the-counter pain drugs; Nyloxin and Pet Pain-Away?, announced today that they are in the process of restructuring their Board of Directors as well as their corporate debt to pave
3/8/18 - Quotidian Technical Highlights on Selected Drug Makers Stocks AbbVie, Biostar Pharma, Bristol-Myers Squibb, and Eli Lilly
Today we are offering reports on ABBV, BSPM, BMY, and LLY which can be accessed for free by signing up to has selected four major players in the Drug Manufacturers space for review today: AbbVie Inc., Biostar Pharmaceuticals Inc., Bristol-Myers Squibb Co., and Eli Lilly and Co.. On Wednesday,
3/8/18 - Shire plc - U.S. FDA Accepts New Drug Application for Prucalopride for Chronic Idiopathic Constipation
The FDA is expected to provide a decision on or around December 21, 2018, the designated Prescription Drug User Fee Act action date with FDA noting that timelines are flexible and subject to change based on workload and identification of potential review issues. 'Today's acceptance of the NDA reinforces the breadth and depth of Shire' s capabilitie
3/8/18 - Ultragenyx Announces Positive Topline Results and DMC Review from First Cohort of Phase 1/2 Clinical Study of DTX301, an Investigational Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency [Sport360]
-Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive longer-term safety and efficacy data from the first dose cohort of the Phase 1/ 2 study of DTX301, an investigational adeno-associated virus gene therapy for the treatment of ornithine.
Articles(s): 1 - 25 of 106     Next >>     Go To Page:

© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement